Regulus Therapeutics Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '25 Jun 30, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024
Net Income	-	-22.46	167.9
Depreciation & Amortization	-	201.08	192.6
Loss (Gain) From Sale of Assets	-	11.7	-2.13
Loss (Gain) From Sale of Investments	-	-24.26	-25.43
Provision & Write-off of Bad Debts	-	0.76	-
Other Operating Activities	-	-29.14	-12.48
Change in Accounts Receivable	-	42.58	-28.1
Change in Inventory	-	13.61	23.77
Change in Accounts Payable	-	-15.56	2.34
Change in Unearned Revenue	-	-13.84	28.95
Change in Other Net Operating Assets	-	22.21	16.61
Operating Cash Flow	-	186.68	364.04
Operating Cash Flow Growth	-	-48.72%	-
Capital Expenditures	-	-48.9	-146.34
Sale of Property, Plant & Equipment	-	6.54	2.25
Investment in Securities	-	18.73	-36.17
Other Investing Activities	-	6.37	5.14
Investing Cash Flow	-	-17.27	-175.12
Long-Term Debt Repaid	-	-37.69	-39.51
Net Debt Issued (Repaid)	-	-37.69	-39.51
Common Dividends Paid	-	-71.84	-100.57
Other Financing Activities	-	-15.91	-27.08
Financing Cash Flow	-	-125.44	-167.16
Foreign Exchange Rate Adjustments	-	-0.78	0.06
Net Cash Flow	-	43.19	21.81
Free Cash Flow	-	137.78	217.7
Free Cash Flow Growth	-	-36.71%	-
Free Cash Flow Margin	-	4.80%	6.54%
Free Cash Flow Per Share	-	23.98	37.88
Cash Interest Paid	-	15.91	26.78
Cash Income Tax Paid	-	28.52	74.05
Levered Free Cash Flow	-	140.33	-
Unlevered Free Cash Flow	-	150.74	-
Change in Net Working Capital	-	-29.17	-

Updated Jan 23, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.